Expression of FKBP51 in breast cancer and its clinical significance
Qingmin Li,Shuya Song,Jing Dong,Yulian Jiao,Yueran Zhao
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2016.16.011
2016-01-01
Abstract:Objective To investigate the expression of FK506 binding protein 51 (FKBP51) in breast cancer and its clinical significance. Methods The expression of FKBP51, AR, ER, PR, HER-2, P53 and Ki-67 was detected by immunohistochemical EliVisionTM method in 140 cases of breast cancer (included intraductal carcinoma and invasive ductal carcinoma, and derived from Xi'an alina biotechnology co.'s chip and pathology department of Shandong provincial hospital), and the 21 cases of fibroadenoma (derived from pathology department of Shandong provincial hospital) being as control groups, to analyze the correlation of FKBP51 expression in breast cancer with clinicopathological features and its relationship with prognosis. Results The positive expression rate of FKBP51 in breast cancer was 36.4%, was obviously lower than that in breast fibroadenoma (66.7%), with significant statistically difference, P=0.008; The positive expression rate of FKBP51 in fibroadenoma, intraductal carcinoma and invasive ductal carcinoma was respectively 66.7%, 43.5% and 35.0%, with significant statistically difference, P=0.023. In invasive ductal carcinoma, the expression of FKBP51 was negatively correlated with histological grade, molecular typing (β=-1.156, P=0.023; r=-0.302, P=0.001), and positively correlated with PR (β=1.210, P=0.000). There was no significant difference between the expression of FKBP51 and clinical tumor TNM stage, lymphatic metastasis number, AR and ER (P>0.05). Conclusion The breast cancer cell with the higher expression of FKBP51 may have the better prognosis, and FKBP51 may inhibit the proliferation of breast cancer cell through steroid hormone receptor pathway.